Blog

Viktor Grunwald: Real-world cabozantinib after ICI

Photo from Viktor Grunwald/X

Sep 14, 2024, 13:51

Viktor Grunwald: Real-world cabozantinib after ICI

Viktor Grunwald, Professor of Interdisciplinary Genitourinary (GU) Oncology at the University Hospital Essen, shared a post on X, about paper published in Clinical Genitourinary Cancer:

Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

Authors: Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, Niegisch Günter, Schnabel Marco, Flörcken Anne, Maasberg Michael, Maintz Christoph, Zahn Mark-Oliver, Wortmann Anke, Hinkel Andreas, Casper Jochen, Darr C, Hilser Thomas, Schulze M, Sookthai Disorn, Ivanyi Philipp.

”Real-world cabozantinib after ICI:

Similar efficacy (shorter OS) compared to METEOR.
62% had lower starting doses (<60mg).
Similar outcome in low vs. 60 mg starting dose.
Less toxicity with lower dose.
Let’s re-think cabozantinib dosing.”

Source: Viktor Grunwald/X

Bögemann Martin Cabozantinib cancer Casper Jochen Clinical Genitourinary Cancer Darr C Flörcken Anne Grünwald Viktor Hilser Thomas Hinkel Andreas Ivanyi Philipp Maasberg Michael Maintz Christoph Niegisch Günter OncoDaily Oncology Rafiyan Mohammad-Reza Schnabel Marco Schulze M Sookthai Disorn University Hospital Essen Viktor Grünwald Wortmann Anke Zahn Mark-Oliver

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage